Soligenix announced that new supportive trial data for its HyBryte treatment for cutaneous T-cell lymphoma will be presented at the United States Cutaneous Lymphoma Consortium Workshop on March 26, 2026. The presentations will occur ahead of the American Academy of Dermatology Annual Meeting and will highlight positive results from a long-term treatment study and a comparative analysis versus Valchlor. This data supports HyBryte's potential as a therapeutic option for CTCL patients.
HyBryte, also known as SGX301 or synthetic hypericin sodium, is a novel photodynamic therapy that utilizes safe visible light for the treatment of cutaneous T-cell lymphoma. The company's Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of this treatment following the successful completion of a second Phase 3 study. Regulatory approvals will be sought to support potential commercialization worldwide based on this clinical data.
The presentation of this new data at a major medical workshop represents a significant step in the clinical development pathway for HyBryte. Cutaneous T-cell lymphoma is a rare form of non-Hodgkin lymphoma that primarily affects the skin, and patients often have limited treatment options. The comparative analysis versus Valchlor, an existing treatment, provides important context for healthcare providers evaluating therapeutic alternatives for their patients.
Beyond HyBryte, Soligenix's development programs include expansion of synthetic hypericin into psoriasis treatment, designated as SGX302. The company is also developing first-in-class innate defense regulator technology with dusquetide for inflammatory diseases including oral mucositis in head and neck cancer patients, and SGX945 for Behcet's Disease. These programs address significant unmet medical needs in rare disease areas.
The company maintains a separate Public Health Solutions business segment focused on vaccine development. This segment includes RiVax, a ricin toxin vaccine candidate, vaccine programs targeting filoviruses such as Marburg and Ebola, and CiVax, a vaccine candidate for COVID-19 prevention. These programs incorporate the proprietary heat stabilization platform technology known as ThermoVax and have received government funding from agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority.
The upcoming presentation of HyBryte data at the USCLC workshop represents an important milestone in the treatment's development timeline. For patients with cutaneous T-cell lymphoma, new treatment options could significantly impact quality of life and disease management. The medical community's reception of this data may influence treatment protocols and patient care approaches for this rare condition. As clinical development progresses, the potential availability of HyBryte could address an important unmet need in oncology and dermatology practice. Additional information about the company is available in their newsroom at https://ibn.fm/SNGX.
